VB Speciality Drugs

• For I.V. Single use only
• For Intravenous use only
• Lyophilized Injection
• For IV use only
• Single dose Vial

• Composition:
• Each vial containa:
• Tigecycline I.P 50 mg.
• Exoplents q.s.

• Each pre-filled syringe contains:
• Adalimumab-40 mg.
• Succinic Acid NF.
• Sodium Chioride USP.
• L-Arginine Monohydraochioride USP.
• Sorbitol NF, Polysorbate 80NF.
• Sodium Hydraoxide NF q.s.
• Water for injection IP q.s.
• Store between + 2

• Each prefilled syringe contains:
• Pegfilgrastim 6 mg.
• Acetate, D-Sorbitol NF,
• Sodium hydroxide NF and water for injection Ip q.s.
• Store between +2

• Each ml of injection contains:
• 250 mg teriparatide (rhPTH1-34) IP as an active injection .
• Glacial acetic (USP), sodium acetate (anhydrous) (USP),Mannitol (USP),meta-cresol (USP).
• Hydrochionic acid solution 10% (NF) q.s.
• Sodium hydroxide solution 10% (NF) q.s.
• Water for injection (USP) q.s.

• Each vial contains:
• Leuprorelin B.P. (as acetate) 11.25 mg.
• Excipients : polyactic acid, mannitol L.P.
• To be reconstituted with diluent (Diluent for LUPRODEX DEPOT) provided wit5h this pack.
• Administer the entire content after reconstitution.
• Dosage: As directed by the physician.
• Refer pack insert for directions ofr administration and precautions for use. 

• Compositione:
• Each Combipack contains:
• (A) Isavuconazole (As isavuconazonium sulfate) 200 mg Powder for concentrate for solution for infusion.
• Each vial contains:
• Isavuconazonium sulfate 372.6 mg equivalent to isavuconazole 200 mg.
• Excipients q.s.
• (B) Sterile water for injections I.P.5 ml
• FFS piastic Ampoule .
• Each Ampoule contains:
• Sterile water for injections I.P.
• Dosage:
• As directed by the physician.
• Storage:
• Store between 2

• The reconstituted product is a milky suspension.
• Warning: to be soid by retail on the prescription of an oncologist only.

• Composition:
• Each vial contains:
• Meropenem I.P.(sterile) Equivalent to anhydrous.
• Meropenem 1000 mg.
• sodium Carbonate I.P.
• Equivalent to sodium 90.2 mg.

• Each vial contains:
• Colistimethate sodium IP.45,00,000 IU (IU: International Units)

• Warning:

•  Cytotoxic agent to be sold by retail on the prescription of an Oncologist / Cancer Hospital/Institution only.
• Caution Not to be sold by retail  without the presaliation of a Registered Medical Practitioner. 
• Batch No.ADC 2003FVA
• Mfg.Lic.No

• -M L No M/100

Other Details:

Each bottle contains:

Total Protein 200 g/i.

Sodium Caprylate 6.65 g/l.

Na* not more than 160 mmol/l.

K*not more than 2 mmol/l.

Aluminium 200 g/l.

Source: Human plasma.

Non-reactive for HBsAg.

HCV,HIV l and ll antibodies and negative for HCV RNA by PCR.

Store at 2

• Each uncooted tablet contains:
• Abiraterone Acetate I.P.  250 mg.
• Excipied  .q.s.

• Colistimethate 
• Sodium IP..45,00,000 IU (IU: International Units)
• Dosage:
• As directed by the physician.
• Refer pack insert for dosage, direction for use and administration.
• Store below 25"C.
• The reconstituted solution should be used within 24 hours when stored at 2-8"C.

• 440 mg multi-use vial.
• each vial of loyphilized powder contains 
• Trastuzumad - 440 mg
• L-Histidine hydrochioride monohydrate EP L-Histidine USP
• a,a-Trehalose dihydrate NF Polysorbate 20 NF . Each vial contains 7.2 ml sterile Bacteriostatic water for injection.
• Store the lyophilized powder and diluent between +2"C and +8"C. 

• The vial is single use container. Any unused portion must be discarded.
• Each vial contains:
• Meropenem trihydrate equivalent to anhydrous meropenem I.P.1 gm.
• Anhydrous sodium carbonate 208 mg.
• Each vial contains 90 mg of sodium.

• Composition:
• Each vial contains:
• Ertapenem sodium equivalent to anhydrous ertapenem 1000 mg .
• Excipients q.s.

• Each multidose cartridge contains:
• Enoxaparin Sodium IP 300mg/3ml.
• (Porcine Derived)
• Benzyl alcohol IP 1.5% w/v.
• (preservative)
• Water for injection IP Q.S.

• Darbepoetin alfa injection causes the bone marrow to produce red blood cells. If the body does not produce enough red blood cells, severe anemia can occur. This often occurs in people with chronic kidney failure whose kidneys are not working properly.

Ceftazidime is a third-generation cephalosporin antibiotic used to treat a variety of bacterial infections, particularly those caused by Gram-negative organisms. It is often used in hospital settings to treat severe infections.

Ceftazidime injection is indicated for the treatment of:

• Lower respiratory tract infections
• Skin and skin structure infections
• Urinary tract infections (complicated and uncomplicated)
• Bacterial septicemia
• Bone and joint infections
• Gynecologic infections
• Intra-abdominal infections, including peritonitis
• Central nervous system infections, including meningitis
• Empirical treatment of febrile neutropenia

Ceftazidime works by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs), disrupting the formation of the bacterial cell wall, which leads to cell lysis and death.

Ceftazidime is administered by intravenous (IV) or intramuscular (IM) injection. The dosage depends on the type and severity of the infection, as well as patient factors such as age and kidney function.

Adult Dosage:

• Typical dosage: 1 to 2 grams every 8 to 12 hours.
• Severe infections, including those caused by Pseudomonas aeruginosa: Up to 2 grams every 8 hours.

Pediatric Dosage:

• 30 to 50 mg/kg every 8 hours, with a maximum of 6 grams per day.
• For neonates (0 to 4 weeks): 30 mg/kg every 12 hours.

Dosage Adjustments:

• Patients with renal impairment require dosage adjustment based on creatinine clearance levels.

Common side effects include:

• Injection site reactions (pain, inflammation)
• Diarrhea
• Nausea and vomiting
• Rash
• Pruritus (itching)
• Headache

Serious side effects may include:

• Severe allergic reactions (anaphylaxis)
• Clostridium difficile-associated diarrhea
• Seizures (particularly in patients with renal impairment)
• Hemolytic anemia
• Thrombocytopenia (low platelet count)
• Hepatotoxicity

• Known hypersensitivity to ceftazidime, cephalosporins, or any component of the formulation.
• Use with caution in patients with a history of penicillin allergy, as cross-reactivity may occur.
• Monitor renal function, particularly in elderly patients and those with pre-existing renal impairment.
• Use with caution in patients with a history of gastrointestinal disease, particularly colitis.

• Aminoglycosides: Concurrent use with aminoglycoside antibiotics increases the risk of nephrotoxicity. Renal function should be monitored.
• Diuretics: High-dose diuretics such as furosemide can also increase the risk of nephrotoxicity when used concurrently with ceftazidime.

• Pregnancy: Classified as Category B. Animal studies have not shown any harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed.
• Breastfeeding: Ceftazidime is excreted in human milk in low concentrations. Caution should be exercised when administering to a nursing woman.
• Elderly Patients: Dose adjustment may be necessary due to age-related decline in renal function.
• Pediatric Use: Generally safe for use in children, with dosage adjustments based on age and weight.

• Store vials at 20°C to 25°C (68°F to 77°F).
• Reconstituted solution should be used immediately or stored according to the manufacturer's guidelines, typically within 12 to 24 hours if refrigerated.

Additional Information:

• Production Capacity: 500
• Delivery Time: 2hr TO 48 hrs
• Packaging Details: Ceftazidime 2GRM/ Avibactam0.5 GRM VIAL.

• Zoladex LA contains goserelin acetate equivalent to goserelin 10.8 mg peptide base in a long acting sustained release implant.
• Also contains lactide/glycolide copolymer.
• For subcutaneous injection.
• To be administered as directed by the physician see enclosed leaflet for directions for use.

• Each vial contains:
• 120 mg of denosumab in 1.7 ml of solution (70mg/ml).
• Store in a refrigerator (2

• Each vial contains:
• colistimethate sodium I.P. 5.500.000 IU (IU: International Units)
• dosage: as directed by the physician. 
• The reconstituted solution should be used immediately or used within 24 hours when stored at 2-8"C.